a16z Perennial Management L.P. Invests $401,000 in Gilead Sciences, Inc. $GILD

a16z Perennial Management L.P. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,614 shares of the biopharmaceutical company’s stock, valued at approximately $401,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new stake in Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC increased its stake in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Gilead Sciences by 16.8% during the second quarter. Venturi Wealth Management LLC now owns 3,331 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 479 shares in the last quarter. Finally, Sax Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 10.6% in the second quarter. Sax Wealth Advisors LLC now owns 2,453 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 236 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Morgan Stanley cut their target price on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. Wells Fargo & Company upped their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Scotiabank began coverage on Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price for the company. Finally, Daiwa Securities Group increased their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.73.

Gilead Sciences Stock Up 2.1%

GILD opened at $152.50 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $153.13. The stock has a market capitalization of $189.20 billion, a P/E ratio of 23.64, a P/E/G ratio of 0.79 and a beta of 0.36. The business has a 50 day simple moving average of $127.38 and a 200-day simple moving average of $120.91.

Insider Buying and Selling

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the sale, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer owned 613,912 shares of the company’s stock, valued at $92,086,800. This represents a 15.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 373,037 shares of company stock valued at $50,731,512 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.